09.17.14
Fiagon AG is on a roll. The German medtech developer has scored American and Chinese clearances for its FlexPointer surgical navigation system and won GE Healthcare's approval to license the firm's ear-nose-throat (ENT) and cranial navigation technologies.
Both the U.S. Food and Drug Administration (FDA) and China Food and Drug Administration have cleared the FlexPointer, an instrument that permits surgical sinus intervention without the need of exchange during the surgery. The pointer is inserted endoscopically assisted and indicates the current position. The unique FlexPointer is navigated at the tip of the instrument and can be intraoperatively adjusted by bending it, the company claims.
The navigated FinePointer is designed to support skull base surgery for ENT access. The very thin FinePointer is navigated at the tip and permits less invasive approaches in keyhole surgery, resulting in less pain and more rapid recovery for the patient, Fiagon noted in a news release.
“We are excited about the excellent acceptance of our technology in Europe, and are looking forward to the penetration of the U.S. and China markets in the coming years, Fiagon CEO Timo Krüger, M.D., said. "Our patent portfolio has been strengthened by the GE license agreement, and coupled with our regulatory clearance, we are ready to expand our sales to the U.S. and to China.”
Fiagon's agreement with GE Healthcare grants Fiagon a patent license to several of GE Healthcare's ENT and Cranial navigation technologies. This agreement will help Fiagon to surround and back up the 35 issued patents and substantial intellectual property of Fiagon. Fiagon will pay cash to GE Healthcare
Fiagon AG medical technologies, a private investor owned company in Berlin, Germany, is the parent company of Fiagon GmbH Holding. Fiagon develops and manufactures surgical navigation systems that incorporate “chip on the tip” technology.
Both the U.S. Food and Drug Administration (FDA) and China Food and Drug Administration have cleared the FlexPointer, an instrument that permits surgical sinus intervention without the need of exchange during the surgery. The pointer is inserted endoscopically assisted and indicates the current position. The unique FlexPointer is navigated at the tip of the instrument and can be intraoperatively adjusted by bending it, the company claims.
The navigated FinePointer is designed to support skull base surgery for ENT access. The very thin FinePointer is navigated at the tip and permits less invasive approaches in keyhole surgery, resulting in less pain and more rapid recovery for the patient, Fiagon noted in a news release.
“We are excited about the excellent acceptance of our technology in Europe, and are looking forward to the penetration of the U.S. and China markets in the coming years, Fiagon CEO Timo Krüger, M.D., said. "Our patent portfolio has been strengthened by the GE license agreement, and coupled with our regulatory clearance, we are ready to expand our sales to the U.S. and to China.”
Fiagon's agreement with GE Healthcare grants Fiagon a patent license to several of GE Healthcare's ENT and Cranial navigation technologies. This agreement will help Fiagon to surround and back up the 35 issued patents and substantial intellectual property of Fiagon. Fiagon will pay cash to GE Healthcare
This agreement enables Fiagon and GE Healthcare to advance minimally invasive procedures in the ENT and cranial fields.
“At GE Healthcare, we believe in the benefits of surgical navigation and are pleased to license technology to Fiagon AG in order to advance minimally invasive procedures in the ENT and cranial fields,” said Amanda Baccarini, chief marketing officer of GE Healthcare Surgery.Fiagon AG medical technologies, a private investor owned company in Berlin, Germany, is the parent company of Fiagon GmbH Holding. Fiagon develops and manufactures surgical navigation systems that incorporate “chip on the tip” technology.